Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients
Predictive Oncology (NASDAQ: POAI) has announced a strategic collaboration with Every Cure, a nonprofit organization, to accelerate drug repurposing for cancer treatment. The partnership leverages POAI's extensive biobank of 150,000+ tumor samples across 130+ cancer types and AI-driven platform that can screen drugs against various tumor types.
Every Cure will utilize POAI's data from testing approximately 150 FDA-approved drugs on patient tumor samples. The nonprofit employs AI models, including knowledge graphs and large language models, to identify potential connections between existing drugs and diseases. The collaboration aims to expedite the discovery of new cancer treatment options while making healthcare more accessible and economically feasible.
Predictive Oncology (NASDAQ: POAI) ha annunciato una collaborazione strategica con Every Cure, un'organizzazione non profit, per accelerare il riposizionamento di farmaci nel trattamento del cancro. La partnership sfrutta la vasta biobanca di POAI, con oltre 150.000 campioni tumorali rappresentanti più di 130 tipi di cancro, e la sua piattaforma basata sull'IA in grado di testare farmaci su diversi tipi di tumore.
Every Cure utilizzerà i dati di POAI derivanti dal test di circa 150 farmaci approvati dalla FDA su campioni tumorali di pazienti. L'organizzazione impiega modelli di intelligenza artificiale, inclusi knowledge graph e large language model, per individuare potenziali collegamenti tra farmaci esistenti e malattie. L'obiettivo della collaborazione è accelerare la scoperta di nuove opzioni terapeutiche per il cancro rendendo l'assistenza sanitaria più accessibile e sostenibile dal punto di vista economico.
Predictive Oncology (NASDAQ: POAI) ha anunciado una colaboración estratégica con Every Cure, una organización sin fines de lucro, para acelerar el reposicionamiento de fármacos en el tratamiento del cáncer. La alianza aprovecha el extenso biobanco de POAI, con más de 150.000 muestras tumorales que abarcan más de 130 tipos de cáncer, y su plataforma impulsada por IA capaz de evaluar fármacos frente a distintos tipos de tumores.
Every Cure empleará los datos de POAI obtenidos al probar aproximadamente 150 fármacos aprobados por la FDA en muestras tumorales de pacientes. La organización utiliza modelos de inteligencia artificial, incluidos knowledge graphs y grandes modelos de lenguaje, para identificar posibles conexiones entre medicamentos existentes y enfermedades. La colaboración pretende acelerar el descubrimiento de nuevas opciones terapéuticas contra el cáncer y hacer la atención sanitaria más accesible y viable económicamente.
Predictive Oncology (NASDAQ: POAI)는 비영리 단체인 Every Cure와 암 치료를 위한 약물 재창출(리포지셔닝)을 가속화하기 위한 전략적 협력을 발표했습니다. 이번 파트너십은 POAI의 방대한 바이오뱅크—130개 이상의 암 유형150,000개 이상의 종양 샘플—과 다양한 종양 유형에 대해 약물을 스크리닝할 수 있는 AI 기반 플랫폼을 활용합니다.
Every Cure는 환자 종양 샘플에서 약 150종의 FDA 승인 약물을 시험한 POAI의 데이터를 활용할 예정입니다. 이 비영리 단체는 지식 그래프와 대형 언어 모델을 포함한 AI 모델을 사용해 기존 약물과 질환 간의 잠재적 연관성을 찾아냅니다. 이번 협력의 목표는 새로운 암 치료 옵션의 발견을 앞당기고 의료 서비스를 보다 접근 가능하고 경제적으로 실현 가능하게 만드는 것입니다.
Predictive Oncology (NASDAQ: POAI) a annoncé une collaboration stratégique avec Every Cure, une organisation à but non lucratif, afin d'accélérer le repositionnement de médicaments pour le traitement du cancer. Le partenariat s'appuie sur la vaste biobanque de POAI, comprenant plus de 150 000 échantillons tumoraux couvrant plus de 130 types de cancer, et sur sa plateforme pilotée par l'IA capable de tester des médicaments sur différents types de tumeurs.
Every Cure exploitera les données fournies par POAI issues des essais d'environ 150 médicaments approuvés par la FDA sur des échantillons tumoraux de patients. L'organisation utilise des modèles d'intelligence artificielle, y compris des knowledge graphs et de grands modèles de langage, pour repérer d'éventuelles connexions entre des médicaments existants et des maladies. L'objectif de la collaboration est d'accélérer la découverte de nouvelles options thérapeutiques contre le cancer tout en rendant les soins de santé plus accessibles et économiquement viables.
Predictive Oncology (NASDAQ: POAI) hat eine strategische Zusammenarbeit mit der gemeinnützigen Organisation Every Cure angekündigt, um die Wirkstoff-Repositionierung für die Krebsbehandlung zu beschleunigen. Die Partnerschaft nutzt POAIs umfangreiche Biobank mit über 150.000 Tumorproben aus mehr als 130 Krebsarten sowie dessen KI-gestützte Plattform, die Wirkstoffe gegen verschiedene Tumorarten screenen kann.
Every Cure wird die Daten von POAI nutzen, die aus Tests von etwa 150 von der FDA zugelassenen Medikamenten an Patienten-Tumorproben stammen. Die gemeinnützige Organisation setzt KI-Modelle ein, darunter Knowledge Graphs und große Sprachmodelle, um potenzielle Zusammenhänge zwischen bestehenden Medikamenten und Krankheiten zu identifizieren. Ziel der Zusammenarbeit ist es, die Entdeckung neuer Krebsbehandlungen zu beschleunigen und die Gesundheitsversorgung zugänglicher und wirtschaftlich tragfähiger zu machen.
- Access to extensive biobank of 150,000+ tumor samples across 130+ cancer types
- Partnership combines complementary AI capabilities for accelerated drug repurposing
- Potential to identify new cancer treatments at lower costs and faster timelines
- Validation of POAI's AI platform through previous successful drug repurposing efforts
- None.
Insights
POAI's AI-driven partnership with Every Cure to repurpose FDA-approved drugs could accelerate cancer treatment discovery while reducing costs substantially.
This strategic collaboration between Predictive Oncology and Every Cure represents a significant advancement in drug repurposing for cancer treatment. By combining POAI's extensive biobank of over 150,000 tumor samples across 130+ cancer types with Every Cure's AI repurposing technologies, the partnership aims to identify new applications for approximately 150 FDA-approved drugs.
The scientific approach is particularly compelling. POAI's platform allows for rapid screening of drugs against various tumor types to predict patient response, while Every Cure employs knowledge graphs and large language models to identify connections between existing drugs and diseases. This complementary AI integration could dramatically accelerate the typical drug development timeline.
Drug repurposing offers substantial advantages over traditional drug development. The typical new drug requires 10-15 years and $1-2 billion to reach market, whereas repurposing existing medications can be accomplished in months rather than decades, at a fraction of the cost. Additionally, repurposed drugs have established safety profiles, reducing risks to patients.
For cancer patients with limited treatment options, this initiative could potentially identify effective therapies from drugs already approved for other conditions. The collaboration specifically targets scenarios where standard treatment options have been exhausted, addressing a critical unmet need in oncology care while promoting more equitable and economically feasible healthcare solutions.
This partnership leverages POAI's proven track record in supporting drug discovery and development while aligning with Every Cure's mission to help the 300+ million people globally battling diseases with no approved treatments. The validation that POAI's platform has already successfully identified drugs for repurposing suggests this collaboration has tangible potential to deliver meaningful clinical results.
Collaboration builds upon positive results utilizing Predictive Oncology’s AI platform to identify new indications for existing drugs
PITTSBURGH, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug development and discovery, and Every Cure, a leading nonprofit dedicated to identifying and validating new uses for existing drugs, today announced a strategic collaboration to identify and prioritize drugs for repurposing to improve patient outcomes and save lives.
Predictive Oncology has a longstanding commitment to supporting the best treatments for patients diagnosed with cancer, through both proprietary clinical assays and AI-driven machine learning (ML). These capabilities allow for the rapid screening of a drug against a broad range of tumor types, with the goal of predicting a patient’s response to an anti-cancer therapy. Predictive Oncology has a long and established track record of supporting various stages of drug discovery and development, enabling drug developers to expand and replenish their pipelines.
Every Cure is a nonprofit on a mission to save and improve lives with repurposed drugs– working to alleviate suffering for more than 300 million people globally who are battling diseases with no approved treatments. The organization leverages AI to identify matches between FDA-approved drugs and known diseases, pinpointing the most promising opportunities for drug repurposing and aiming to deliver treatments to patients in months rather than decades, at a fraction of the cost of new drug development.
“The synergy between each organization’s AI assets and expertise are clearly complementary in serving the intended purpose of accelerating drug repurposing while overcoming barriers to these efforts,” said Dr. Arlette Uihlein, SVP, Translational Medicine and Drug Discovery, Medical Director at Predictive Oncology. “As Every Cure scales its approach to meet these challenges, we believe we are the perfect partner, capable of generating data on patient tumor response to drugs in a fraction of the time and at far less cost than more traditional approaches.”
Every Cure seeks to use data generated by Predictive Oncology, which pairs patient tumor samples with approximately 150 FDA-approved drugs, each of which have been approved for at least one specific clinical indication. This repurposing effort allows for existing drugs to be used in new indications, which aligns closely with the strengths and capabilities of Predictive Oncology’s platform.
“The intersecting interests and expertise of our two organizations perfectly aligns with our drug repurposing efforts, seeking to identify treatments to be used when standard treatments options have been exhausted, while also promoting equitable and economically feasible healthcare,” said Every Cure’s Dr. David Fajgenbaum. “Collaborating with Predictive Oncology on this endeavor not only supports our mission but advances our cause.”
“This collaboration on drug repurposing leverages our unique assets and capabilities, most notably our vast biobank of more than 150,000 tumor samples across more than 130 different cancer types,” said Raymond F. Vennare, CEO of Predictive Oncology. “Together we believe we can make a meaningful difference in the lives of patients in need, and we are pleased to be able to assist Every Cure in advancing these efforts”
Every Cure’s AI models use knowledge graphs, large language models, and real-world medical data to identify and rank potential connections between existing drugs and diseases. Top-ranked opportunities are then rigorously evaluated by the experienced team at Every Cure, who determine what is needed to bring them safely to patients. In some cases, Every Cure generates additional pre-clinical or clinical evidence and engages with research partners, regulators, and patient organizations to maximize patient impact and ensure treatments reach those who need them. Predictive Oncology’s ML models use AI to predict patient tumor drug response, based on wet lab testing which accesses the thousands of human tumor samples and associated data housed at Predictive Oncology’s CLIA lab. One application of the platform, which has already been validated and deployed, has been used to identify drugs for repurposing.
About Every Cure
Every Cure is a nonprofit biotech organization committed to unlocking the potential of existing medicines to treat as many diseases as possible. By harnessing AI-driven platforms, rigorous preclinical and clinical testing, and global dissemination strategies, Every Cure accelerates the delivery of life-saving treatments to patients worldwide. Every Cure has been profiled on Good Morning America, USA Today, and the Wall Street Journal and selected as both an Audacious Project grantee from TED and a Founder’s Prize recipient from Elevate Prize Foundation. Learn more at www.everycure.org.
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with
Investor Relations Contact
Mike Moyer
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Forward-Looking Statements
Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the company disclaims any intent or obligation to update these forward-looking statements.
FAQ
What is the purpose of the collaboration between Predictive Oncology (POAI) and Every Cure?
How many tumor samples and cancer types does Predictive Oncology (POAI) have in its biobank?
How many FDA-approved drugs will be tested in POAI's drug repurposing program?
What technology does Every Cure use for drug repurposing research?
How does Predictive Oncology's AI platform contribute to drug repurposing?
